pubrio
Dove Medical Press logo

Dove Medical Press

Public
dovepress.com
出版行业200+ employeesFounded 2003🇬🇧 英国

Dove Medical Press Ltd is an online open access academic publisher specialising in science, technology and especially medicine. All 80 peer-reviewed journals are free to access online, allowing authors to disseminate their research to a global audience. Most of our journals are widely indexed in databases such as PubMed, Scopus and DOAJ, and an increasing number have Impact Factors. We are a member of OASPA, COPE and HINARI, and are committed to publishing good scientific research and giving authors around the world the opportunity to publish and share their research findings. We have an efficient and rigorous peer-review process. Due to this, many of our journals are able to provide authors with an initial editorial decision within four to five weeks. We aim to provide the highest possible standard of service to our authors. Recent feedback from an author survey demonstrated that: • 100% of authors surveyed found the online manuscript system easy to use • 100% of authors surveyed agreed that they received professional accurate service • 97% of authors surveyed would submit a manuscript with us again • 96% of authors surveyed received prompt communication throughout the publishing process • 86% of authors surveyed rated their level of satisfaction as Excellent (the other 14% rated us as good) To view testimonials from more of our authors please visit: https://www.dovepress.com/testimonials.php We have offices in the United Kingdom, USA and New Zealand. Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC.

成立年份
2003
员工人数
200+
行业
出版行业
公司类型
Public Company
总部
🇬🇧Beechfield House, Winterton Way, Macclesfield, Cheshire East, United Kingdom (+3)
专长
信息技术与服务出版行业医疗保健
1 / 2
活跃市场
1
新市场
CN
置信度
多为早期信号
-100%
势头
较上一周期
11 / 100
扩张评分
早期
阶段2探索中
1 个信号 · 最近 90 天

全球扩张

实时
NZCN
阶段
探索中投入中进入中运营中

活动脉搏

最近 90 天内有 1 个信号。

最近 90 天
招聘
0
无活动
营销与公关
0
无活动
产品与技术
1已结束
产品发布
+2个类别已锁定
已显示 5 个中的 3 个

市场进入时间线

该公司进入各个市场的顺序 — 从最早到最新

1
🇳🇿NZ进入的第 1st 个市场 · 2023推进中
探索中
1 个信号探索中 阶段
2
🇨🇳CN进入的第 2nd 个市场 · 2026推进中
探索中
1 个信号探索中 阶段
当前阶段探索中试探市场
置信度44%
开始追踪于2023首个信号

近期信号

产品发布🇨🇳 CN2个月前

和铂医药宣布HBM9378的I期临床试验结果积极

注册以查看完整信号动态

了解一下

关于 Dove Medical Press 的常见问题

关于 Dove Medical Press 的业务、市场和增长信号的快速解答。

Dove Medical Press Ltd is an online open access academic publisher specialising in science, technology and especially medicine. All 80 peer-reviewed journals are free to access online, allowing authors to disseminate their research to a global audience. Most of our journals are widely indexed in databases such as PubMed, Scopus and DOAJ, and an increasing number have Impact Factors. We are a member of OASPA, COPE and HINARI, and are committed to publishing good scientific research and giving authors around the world the opportunity to publish and share their research findings. We have an efficient and rigorous peer-review process. Due to this, many of our journals are able to provide authors with an initial editorial decision within four to five weeks. We aim to provide the highest possible standard of service to our authors. Recent feedback from an author survey demonstrated that: • 100% of authors surveyed found the online manuscript system easy to use • 100% of authors surveyed agreed that they received professional accurate service • 97% of authors surveyed would submit a manuscript with us again • 96% of authors surveyed received prompt communication throughout the publishing process • 86% of authors surveyed rated their level of satisfaction as Excellent (the other 14% rated us as good) To view testimonials from more of our authors please visit: https://www.dovepress.com/testimonials.php We have offices in the United Kingdom, USA and New Zealand. Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC.

今天就开启旅程

可以先用平台,也可以先聊聊

你可以自行使用 Pubrio,或让我们的团队协助研究、获客或数据整合。

与团队沟通
Start Journey Image
pubrio

Pubrio 将来自 50+ 本地来源的商业、人物与意向数据整合为全球图谱,帮助 AI 与营收团队洞悉全市场。

© 2026 Pubrio。保留所有权利。